[go: up one dir, main page]

MX2018000024A - Formulaciones mezcladas. - Google Patents

Formulaciones mezcladas.

Info

Publication number
MX2018000024A
MX2018000024A MX2018000024A MX2018000024A MX2018000024A MX 2018000024 A MX2018000024 A MX 2018000024A MX 2018000024 A MX2018000024 A MX 2018000024A MX 2018000024 A MX2018000024 A MX 2018000024A MX 2018000024 A MX2018000024 A MX 2018000024A
Authority
MX
Mexico
Prior art keywords
formulation
colloidal particles
aoi
present
deformable
Prior art date
Application number
MX2018000024A
Other languages
English (en)
Other versions
MX381075B (es
Inventor
Henry William
Wolf Garraway Richard
Original Assignee
Sequessome Tech Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511478.8A external-priority patent/GB201511478D0/en
Priority claimed from GBGB1511469.7A external-priority patent/GB201511469D0/en
Application filed by Sequessome Tech Holdings Limited filed Critical Sequessome Tech Holdings Limited
Publication of MX2018000024A publication Critical patent/MX2018000024A/es
Publication of MX381075B publication Critical patent/MX381075B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una formulación que comprende mezclas de formulaciones (o dispersiones coloidales) y su aplicación tópica. La formulación comprende al menos dos tipos diferentes de dispersión coloidal que comprenden partículas coloidales deformables, en donde las partículas coloidales deformables comprenden un tensioactivo no iónico y / o un fosfolípido. Las partículas coloidales deformables de la invención pueden comprender un agente de interés (AOI) o pueden estar libres de un AOI. La formulación puede comprender un AOI que no está asociado con las partículas coloidales deformables. La presente invención también incluye kits que comprenden la formulación de la presente invención y el uso de la formulación en medicina, cuidado de la piel y cosméticos.
MX2018000024A 2015-06-30 2016-06-30 Formulaciones mezcladas. MX381075B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1511478.8A GB201511478D0 (en) 2015-06-30 2015-06-30 Blended formulations
GBGB1511469.7A GB201511469D0 (en) 2015-06-30 2015-06-30 Compositions
PCT/EP2016/065415 WO2017001617A1 (en) 2015-06-30 2016-06-30 Blended formulations

Publications (2)

Publication Number Publication Date
MX2018000024A true MX2018000024A (es) 2018-06-27
MX381075B MX381075B (es) 2025-03-12

Family

ID=56292753

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2018000024A MX381075B (es) 2015-06-30 2016-06-30 Formulaciones mezcladas.
MX2018000021A MX382034B (es) 2015-06-30 2016-06-30 Composiciones multifásicas.
MX2021004766A MX2021004766A (es) 2015-06-30 2016-06-30 Composiciones multifásicas.
MX2021003510A MX2021003510A (es) 2015-06-30 2017-12-20 Formulaciones mezcladas.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2018000021A MX382034B (es) 2015-06-30 2016-06-30 Composiciones multifásicas.
MX2021004766A MX2021004766A (es) 2015-06-30 2016-06-30 Composiciones multifásicas.
MX2021003510A MX2021003510A (es) 2015-06-30 2017-12-20 Formulaciones mezcladas.

Country Status (14)

Country Link
US (5) US10744090B2 (es)
EP (3) EP3316856B1 (es)
JP (2) JP6851998B2 (es)
CA (2) CA3026466A1 (es)
DK (2) DK3316856T3 (es)
EA (2) EA038208B1 (es)
ES (2) ES2879383T3 (es)
HR (2) HRP20211669T1 (es)
HU (2) HUE056161T2 (es)
LT (2) LT3316857T (es)
MX (4) MX381075B (es)
PL (2) PL3316857T3 (es)
PT (2) PT3316857T (es)
WO (2) WO2017001625A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3316856T3 (da) 2015-06-30 2021-06-28 Sequessome Tech Holdings Limited Blandede formuleringer
WO2017136600A1 (en) 2016-02-04 2017-08-10 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
BR112020002222A2 (pt) 2017-08-03 2020-07-28 ALASTIN Skincare, Inc. composições e métodos para melhora da flacidez da pele e do contorno corporal
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
JP2025099708A (ja) * 2023-12-22 2025-07-03 小林製薬株式会社 外用組成物

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372296A (en) 1980-11-26 1983-02-08 Fahim Mostafa S Treatment of acne and skin disorders and compositions therefor
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
JPS63501289A (ja) 1985-09-27 1988-05-19 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア リポソ−ム経皮薬剤供給系
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
WO1994001089A1 (de) 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
FR2714596B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
CA2204493C (en) 1994-11-04 2009-04-14 Polymun Scientific Immunbiologische Forschung Gmbh Application of superoxide dismutase in liposomes
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
IL122084A (en) 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
CZ299116B6 (cs) 1997-11-19 2008-04-30 Intendis Gmbh Prípravek s kyselinou azelainovou
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
CA2283574A1 (en) * 1998-01-16 1999-07-22 Color Access, Inc. Stabilized whitening compositions and method of preparing same
MXPA01002149A (es) 1998-09-01 2003-03-27 Idea Ag Transporte electricamente controlado de penetrantes cargados a traves de barreras.
NZ332905A (en) 1998-11-19 2000-12-22 Immuno Lab Ltd Transdermal pharmaceutical composition comprising liposomal bee venom
CN1320880C (zh) 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
GB9902527D0 (en) 1999-02-04 1999-03-24 Phares Pharm Res Nv Compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
US7166297B2 (en) 2000-04-12 2007-01-23 Liplasome Pharma A/S Lipid-based drug delivery systems against parasitic infections
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
CA2448627A1 (en) 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
US20050123593A1 (en) 2001-06-25 2005-06-09 Jonathan Thompson Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
NZ534377A (en) 2002-03-13 2008-04-30 Collagenex Pharm Inc Water-based topical delivery system consisting of cholesterol, fatty acids water and a phospholipid/ceramide portion.
CN100496480C (zh) * 2002-04-22 2009-06-10 宝洁公司 在含水表面活性剂组合物中包括含锌物质的个人护理组合物
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
CN1470234A (zh) * 2002-07-23 2004-01-28 吴翠栓 皮肤用辣椒碱脂质体制剂
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
PL377202A1 (pl) 2002-10-11 2006-01-23 Idea Ag Agregat o zwiększonej odkształcalności, zawierający co najmniej trzy środki amfipatyczne, dla usprawnienia transportu przez półprzepuszczalne bariery oraz do nieinwazyjnego podawania leku in vivo, zwłaszcza przez skórę
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
CA2524478A1 (en) 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
EP1514539A3 (en) * 2003-05-14 2005-05-04 Signal Investment & Management Co. Micro-encapsulated topical analgesic for pain relief and sleeve comprising it
BRPI0412882A (pt) 2003-07-21 2006-10-03 Vasogen Ireland Ltd uso de uma quantidade de corpos farmaceuticamente aceitáveis que portam um número eficaz de grupos contendo fosfato
JP2005179313A (ja) 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
EP1811961A2 (en) 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
UA89545C2 (uk) 2005-08-29 2010-02-10 Сепсикюр Л.Л.К. Спосіб лікування чи попередження станів, викликаних грампозитивними бактеріями
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
EP1968567B1 (en) 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
WO2008039989A2 (en) 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
CN101541308B (zh) 2006-09-28 2012-02-01 哈达斯特医疗研究服务和开发有限公司 甘油磷脂用于关节润滑的用途
JP4732307B2 (ja) 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) * 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
KR20110128283A (ko) 2009-02-05 2011-11-29 타겟티드 딜리버리 테크놀러지스 리미티드 미생물체의 증식 및 생존도를 감소시키는 방법
DK2437726T3 (en) 2009-06-03 2018-08-13 Sequessome Tech Holdings Limited FORMS FOR TREATING DEEP TISSUE Pain
CA2774891A1 (en) 2009-08-21 2011-02-24 Targeted Delivery Technologies Limited Vesicular formulations
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
US20120294924A1 (en) 2011-04-29 2012-11-22 Thomas Tice Peptide-Lipid Conjugates And Uses Thereof
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
EP3027219A1 (en) 2013-07-31 2016-06-08 Sequessome Technology Holdings Limited Vesicles
DK3316856T3 (da) 2015-06-30 2021-06-28 Sequessome Tech Holdings Limited Blandede formuleringer
EP3979975A4 (en) * 2019-06-04 2023-11-01 Aquavit Pharmaceuticals Inc. METHODS AND COMPOSITIONS FOR MICRO-FILLING SKIN WITH HYALURONIC ACID USING MICROCHANNEL TECHNOLOGY

Also Published As

Publication number Publication date
WO2017001625A1 (en) 2017-01-05
HRP20211669T1 (hr) 2022-02-18
CA3026466A1 (en) 2017-01-05
HRP20210903T1 (hr) 2021-09-17
HUE056161T2 (hu) 2022-01-28
DK3316857T3 (da) 2021-10-18
HK1254980A1 (zh) 2019-08-02
EP3316857A1 (en) 2018-05-09
PL3316857T3 (pl) 2022-01-31
EA038208B1 (ru) 2021-07-23
EA038613B1 (ru) 2021-09-23
PT3316856T (pt) 2021-07-06
MX381075B (es) 2025-03-12
PL3316856T3 (pl) 2021-10-25
EA201890119A1 (ru) 2018-07-31
US20210023007A1 (en) 2021-01-28
MX2021004766A (es) 2022-11-07
MX382034B (es) 2025-03-13
HUE054749T2 (hu) 2021-09-28
EP3316856A1 (en) 2018-05-09
MX2021003510A (es) 2021-05-27
EA201890120A1 (ru) 2018-07-31
EP3954361A1 (en) 2022-02-16
US20190167588A1 (en) 2019-06-06
JP2021091730A (ja) 2021-06-17
US20180311148A1 (en) 2018-11-01
MX2018000021A (es) 2018-03-15
US20220370353A9 (en) 2022-11-24
HK1254979A1 (zh) 2019-08-02
US10744090B2 (en) 2020-08-18
JP6851998B2 (ja) 2021-03-31
JP2018522876A (ja) 2018-08-16
US20210007989A1 (en) 2021-01-14
US11547665B2 (en) 2023-01-10
WO2017001617A1 (en) 2017-01-05
DK3316856T3 (da) 2021-06-28
EP3316857B1 (en) 2021-08-04
CA3026484A1 (en) 2017-01-05
PT3316857T (pt) 2021-11-03
LT3316857T (lt) 2021-11-25
EP3316856B1 (en) 2021-04-07
ES2895910T3 (es) 2022-02-23
ES2879383T3 (es) 2021-11-22
US20240099976A1 (en) 2024-03-28
LT3316856T (lt) 2021-07-12

Similar Documents

Publication Publication Date Title
MX2021003510A (es) Formulaciones mezcladas.
MX2018009824A (es) Composiciones para el cuidado personal.
BR112017022021A2 (pt) aplicação de agente anticaspa solúvel em tensoativo
BR112015030649A2 (pt) sanitizante a base de álcool com sensação e compatibilidade dérmica melhoradas
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
GT201400285A (es) Formulacion de anticuerpos
BR112015003963A2 (pt) dispersões de cera aquosas e composições de modelação do cabelo contendo as mesmas
BR112017003883A2 (pt) dispositivos cruzados de apresentação de aplicativo dividido
MX2019008544A (es) Nueva formulacion estable para anticuerpos anti-fxia.
BR112018069478A2 (pt) panos de não tecido com propriedades de aprimoramento de barreira aditivas.
BR112015028499A2 (pt) Peptídeo para induzir apoptose específica de mastócito e uso do mesmo
MY197938A (en) Cosmetic composition of dispersion formulation comprising spherical particle
BR112017025043A2 (pt) formulação para cuidado dos cabelos
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
MX381328B (es) Composiciones que comprenden tensoactivos específicos y altos niveles de glicerina.
BR112016029278A2 (pt) composição cosmética compreendendo um polímero espessante que tem porções hidrofóbicas e hidrofílicas
FR3010899B1 (fr) Composition cosmetique comprenant une association d'agents tensioactifs anioniques de types carboxylate et acyl-isethionate.
BR112017013208A2 (pt) uso de octenidina
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento
BR112015032449A2 (pt) composição e processo em particular para o cuidado, a limpeza e/ou o condicionamento das matérias queratínicas
BR112015032234A2 (pt) composição e processo em particular para o cuidado, a limpeza e/ou o condicionamento das matérias queratínicas
EA202191803A2 (ru) Смешанные составы
PL414021A1 (pl) Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów
TR201905694T4 (tr) Aripiprazol ön ilaç bileşimleri.